[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Trinity Biotech USA\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":75},{"warningLetters":4,"total":74},[5,31,53],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},373,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-01-13T05:00:00Z\">01\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-23T05:00:00Z\">12\u002F23\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flxr-biotech-llc-714568-12232025\">LXR Biotech, LLC\u003C\u002Fa>","Human Foods Program","CGMP\u002FDietary Supplement\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Anthony G. Orzechowski\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>LXR Biotech, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2983 Waterview Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rochester Hills\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48309-4600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Tonyo@lxrbiotech.com\"> Tonyo@lxrbiotech.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 23, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS #613418\u003C\u002Fp>\u003Cp>Dear Mr. Orzechowski,\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 2983 Waterview Dr., Rochester Hills, MI 48309 on February 25, 2025 through March 12, 2025. Based on inspectional findings, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on March 12, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated April 3, May 2, and June 12, 2025, and we address you responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection of your facility on February 25, 2025 through March 12, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements Eternal Energy Grape and Eternal Energy Tropical Punch manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. Your firm did not establish product specifications for identity, purity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, your dietary supplement products Eternal Energy Tropical Punch and Eternal Energy Grape are manufactured using \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, these ingredients are not included in your finished product specifications document.\u003C\u002Fp>\u003Cp>We have reviewed your response dated May 2, 2025, including the finished product labels and finished product specification documents you provided. Your response states that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and that your Eternal Energy Grape and Eternal Energy Tropical Punch products have been “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, the finished product specification documents included with your response do not include all of the dietary ingredients listed in the new Energy Premix. For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> with your response for your Eternal Energy Grape and Eternal Energy Tropical Punch products.\u003C\u002Fp>\u003Cp>In addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\u003C\u002Fp>\u003Cp>2. Your firm failed to establish an identity specification for each component that you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1). Specifically, your specification document for the ingredient “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is used in the manufacture of your Eternal Energy Tropical Punch product, states that you \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your specification document for your ingredient “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is used in the manufacture of your Eternal Energy Grape product, states that you \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, because there are other substances that share the same established criteria, analysis of the factors listed above does not provide unique information that is specific to each of these ingredients and thus cannot confirm the identity of each ingredient.\u003C\u002Fp>\u003Cp>3. You did not ensure that the tests and examinations you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1). Specifically, the finished product Eternal Energy Grape uses the component “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” (listed as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” in the Batch Production Record). According to firm management, identity testing for this component is conducted by a third-party laboratory. Firm management stated that the supplier of your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. When the investigator requested identity testing results for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your firm provided a certificate of analysis for \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the third-party laboratory dated October 7, 2024, which showed the description of the sample as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and the description of the standard it was tested against as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The lot number of the tested material is identical to the supplier-provided reference standard. Your firm management was unaware of what material your supplier sent to the third-party laboratory to use as a reference standard, or if the material sent to the third-party laboratory was a valid standard to test against the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We have reviewed your response dated May 2, 2025. In your response, you state that the certificates of analysis from your supplier “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Further, you state that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” Thus, you state that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, for each specification that you are required to establish, you must take specific actions, after they are established, to verify that the specifications are met, as required by 21 CFR 111.73 and 21 CFR 111.75.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Lauren Crivellone, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS # 613418 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, J.D., M.B.A.\u003Cbr>Acting Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nMr. Anthony G. Orzechowski\n\nRecipient Title\n\nVice President and Chief Operating Officer\n\nLXR Biotech, LLC\n\n2983 Waterview Dr.\n\nRochester Hills, MI 48309-4600\n\nUnited States\n\nTonyo@lxrbiotech.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nDecember 23, 2025\nWARNING LETTER\nCMS #613418\nDear Mr. Orzechowski,\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 2983 Waterview Dr., Rochester Hills, MI 48309 on February 25, 2025 through March 12, 2025. Based on inspectional findings, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on March 12, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated April 3, May 2, and June 12, 2025, and we address you responses below.\nAdulterated Dietary Supplements\nThe inspection of your facility on February 25, 2025 through March 12, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause the dietary supplements Eternal Energy Grape and Eternal Energy Tropical Punch manufactured at your facility to be adulterated within the meaning of section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1. Your firm did not establish product specifications for identity, purity, strength, and composition of the finished batch of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, your dietary supplement products Eternal Energy Tropical Punch and Eternal Energy Grape are manufactured using (b)(4). However, these ingredients are not included in your finished product specifications document.\nWe have reviewed your response dated May 2, 2025, including the finished product labels and finished product specification documents you provided. Your response states that “(b)(4)” and that your Eternal Energy Grape and Eternal Energy Tropical Punch products have been “(b)(4).” However, the finished product specification documents included with your response do not include all of the dietary ingredients listed in the new Energy Premix. For example, (b)(4) with your response for your Eternal Energy Grape and Eternal Energy Tropical Punch products.\nIn addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\n2. Your firm failed to establish an identity specification for each component that you use in the manufacture of a dietary supplement, as required by 21 CFR 111.70(b)(1). Specifically, your specification document for the ingredient “(b)(4),” which is used in the manufacture of your Eternal Energy Tropical Punch product, states that you (b)(4). Your specification document for your ingredient “(b)(4),” which is used in the manufacture of your Eternal Energy Grape product, states that you (b)(4). However, because there are other substances that share the same established criteria, analysis of the factors listed above does not provide unique information that is specific to each of these ingredients and thus cannot confirm the identity of each ingredient.\n3. You did not ensure that the tests and examinations you use to determine whether the specifications are met are appropriate, scientifically valid methods, as required by 21 CFR 111.75(h)(1). Specifically, the finished product Eternal Energy Grape uses the component “(b)(4)” (listed as “(b)(4)” in the Batch Production Record). According to firm management, identity testing for this component is conducted by a third-party laboratory. Firm management stated that the supplier of your (b)(4). When the investigator requested identity testing results for (b)(4), your firm provided a certificate of analysis for (b)(4) from the third-party laboratory dated October 7, 2024, which showed the description of the sample as “(b)(4)” and the description of the standard it was tested against as “(b)(4).” The lot number of the tested material is identical to the supplier-provided reference standard. Your firm management was unaware of what material your supplier sent to the third-party laboratory to use as a reference standard, or if the material sent to the third-party laboratory was a valid standard to test against the (b)(4).\nWe have reviewed your response dated May 2, 2025. In your response, you state that the certificates of analysis from your supplier “(b)(4).” Further, you state that “(b)(4).” Thus, you state that “(b)(4).” However, for each specification that you are required to establish, you must take specific actions, after they are established, to verify that the specifications are met, as required by 21 CFR 111.73 and 21 CFR 111.75.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Lauren Crivellone, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS # 613418 on any submissions and within the subject line of any emails to us. If you have any questions, you may email at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, J.D., M.B.A.\nActing Director, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","LXR Biotech, LLC","lxr-biotech-llc-714568-12232025","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flxr-biotech-llc-714568-12232025","2026-10-26T08:09:17.368077+00:00","Warning Letter","Issued","2026-01-13","714568","Dietary Supplements","Mr. Anthony G. Orzechowski","2026-08-19T07:17:50.647+00:00","Via Email","2025-12-23",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":16,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":48,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},1963,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-08-01T13:20:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-07-17T04:00:00Z\">07\u002F17\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flxr-biotech-llc-652756-07172023\">LXR Biotech, LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations III ","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Andrew H. Krause\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>LXR Biotech, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2983 Waterview Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Rochester Hills\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48309-4600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations III \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 17, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL #652756\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Krause:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, LXR Biotech, LLC, FEI 3010744574, at 2983 Waterview Dr., Rochester Hills from January 9 to 20, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your February 3, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because, while you indicate that you no longer manufacture drugs, you did not provide any specific corrective actions and preventive actions (CAPA) for the violations, including addressing whether the drug products will be removed from the market.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nYour firm contract manufactured an over-the-counter (OTC) \u003Cstrong>(b)(4) \u003C\u002Fstrong>drug product (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>). You failed to conduct adequate testing on components used to manufacture this drug product. Additionally, your firm accepted components from suppliers without establishing the reliability of suppliers’ test analyses. You also did not routinely obtain or review the suppliers’ certificate of analysis (COA) for components (e.g., the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong>). For instance, you provided only a certificate of conformance for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> component.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have appropriate assurance that the components conform to appropriate specifications prior to use in the drug products you manufacture.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to conduct adequate release testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. You only conducted heavy metals and microbiological testing prior to batch release.\u003C\u002Fp>\n\n\u003Cp>Full release testing, which includes strength and identity testing of the active ingredient (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>), must be performed before drug product batch release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that drug product batches conform to appropriate specifications before release.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately qualify the equipment and validate the processes used to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. You have not performed process performance qualification (PPQ) studies, nor do you have a meaningful ongoing program for monitoring process control, to ensure stable manufacturing operations and consistent drug quality.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation, at www.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacture of drug products. For example, you failed to ensure:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>An adequate complaint handling process (21 CFR 211.198).\u003C\u002Fli>\n\t\u003Cli>Adherence to an adequate stability program (21 CFR 211.166(a)).\u003C\u002Fli>\n\t\u003Cli>Consistent and complete batch records (21 CFR 211.188).\u003C\u002Fli>\n\t\u003Cli>Adequate investigations into non-conformances (21 CFR 211.192).\u003C\u002Fli>\n\t\u003Cli>Appropriate examination of labeling and packaging materials for correctness, including but not limited to sufficiently accounting for all ingredients used in manufacturing, prior to packaging operations (21 CFR 211.130(d)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>There was a fundamental failure of production management to effectively oversee the procedures, practices, and suitability of the manufacturing operations. In addition, even when a QU consists of one or only a few, those persons are still accountable for overseeing ongoing effectiveness of all systems and procedures, and review of the results of manufacture to ensure state of control and adherence to all quality standards.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of drugs at this facility. Please verify you no longer manufacture drugs and provide us with a detailed list of the name and NDC numbers for those products. Additionally, respond to this letter by informing FDA if you are currently the manufacturer of any \u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> products for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume any operations regulated under the FD&amp;C Act, notify this office prior to resuming your drug manufacturing operations. If you resume CGMP activities at this or another facility, you are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\u003C\u002Fp>\n\n\u003Cp>If you resume CGMP activities, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARMA3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Sneha Patel\u003Cbr>\nCompliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Case Number above (#652756). If you have questions regarding the contents of the letter, please contact Ms. Patel at (313) 393-8254.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Jeffrey D. Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Andrew H. Krause\n\nRecipient Title\n\nPresident and CEO\n\nLXR Biotech, LLC\n\n2983 Waterview Dr.\n\nRochester Hills, MI 48309-4600\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nJuly 17, 2023\n\nWARNING LETTER\n\nWL #652756\n\nDear Mr. Krause:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, LXR Biotech, LLC, FEI 3010744574, at 2983 Waterview Dr., Rochester Hills from January 9 to 20, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your February 3, 2023, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because, while you indicate that you no longer manufacture drugs, you did not provide any specific corrective actions and preventive actions (CAPA) for the violations, including addressing whether the drug products will be removed from the market.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm contract manufactured an over-the-counter (OTC) (b)(4) drug product (e.g., (b)(4)). You failed to conduct adequate testing on components used to manufacture this drug product. Additionally, your firm accepted components from suppliers without establishing the reliability of suppliers’ test analyses. You also did not routinely obtain or review the suppliers’ certificate of analysis (COA) for components (e.g., the active ingredient (b)(4)). For instance, you provided only a certificate of conformance for your (b)(4) component.\n\nWithout adequate testing, you do not have appropriate assurance that the components conform to appropriate specifications prior to use in the drug products you manufacture.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).\n\nYour firm failed to conduct adequate release testing of (b)(4) drug product. You only conducted heavy metals and microbiological testing prior to batch release.\n\nFull release testing, which includes strength and identity testing of the active ingredient (e.g., (b)(4)), must be performed before drug product batch release and distribution. Without adequate testing, you do not have adequate scientific evidence to assure that drug product batches conform to appropriate specifications before release.\n\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYour firm failed to adequately qualify the equipment and validate the processes used to manufacture (b)(4) drug product. You have not performed process performance qualification (PPQ) studies, nor do you have a meaningful ongoing program for monitoring process control, to ensure stable manufacturing operations and consistent drug quality.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately to ensure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality are necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation, at www.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacture of drug products. For example, you failed to ensure:\n\nAn adequate complaint handling process (21 CFR 211.198).\n\nAdherence to an adequate stability program (21 CFR 211.166(a)).\n\nConsistent and complete batch records (21 CFR 211.188).\n\nAdequate investigations into non-conformances (21 CFR 211.192).\n\nAppropriate examination of labeling and packaging materials for correctness, including but not limited to sufficiently accounting for all ingredients used in manufacturing, prior to packaging operations (21 CFR 211.130(d)).\n\nThere was a fundamental failure of production management to effectively oversee the procedures, practices, and suitability of the manufacturing operations. In addition, even when a QU consists of one or only a few, those persons are still accountable for overseeing ongoing effectiveness of all systems and procedures, and review of the results of manufacture to ensure state of control and adherence to all quality standards.\n\nDrug Production\n\nWe acknowledge your commitment to cease production of drugs at this facility. Please verify you no longer manufacture drugs and provide us with a detailed list of the name and NDC numbers for those products. Additionally, respond to this letter by informing FDA if you are currently the manufacturer of any (b)(4) or (b)(4) products for (b)(4).\n\nIf you plan to resume any operations regulated under the FD&C Act, notify this office prior to resuming your drug manufacturing operations. If you resume CGMP activities at this or another facility, you are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\n\nIf you resume CGMP activities, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system1 audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all CAPAs before you pursue resolution of your firm’s compliance status with FDA.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fcontract-manufacturing-arrangements-drugs-quality-agreements-guidance-industry.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARMA3_RESPONSES@fda.hhs.gov\n\nAttention: Sneha Patel\n\nCompliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter Case Number above (#652756). If you have questions regarding the contents of the letter, please contact Ms. Patel at (313) 393-8254.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Jeffrey D. Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\n______________________\n\n1 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","lxr-biotech-llc-652756-07172023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flxr-biotech-llc-652756-07172023","2026-10-26T08:09:17.316717+00:00","2023-08-01","652756","Drugs","Division of Pharmaceutical Quality Operations III","Mr. Andrew H. Krause","2026-08-20T00:50:18.654+00:00","UPS Next Day","2023-07-17",{"id":54,"raw":55,"subject":59,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":69,"closeout_date":19,"issuing_office":11,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},893,[56,57,58,11,59,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-30T04:00:00Z\">09\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdalai-biotech-company-ltd-690671-09302024\">Dalai Biotech Company Ltd\u003C\u002Fa>","Low Acid Canned Food Regulation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tseng C. Mei\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman of the Board\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Dalai Biotech Company Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10 Minzhi Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tongluo Township\u003C\u002Fspan>, \u003Cspan>Miaoli County\u003C\u002Fspan> \u003Cspan>366001\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Taiwan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:dalai@lailai3211.com.tw\"> dalai@lailai3211.com.tw\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Reference No. 690671\u003C\u002Fp>\u003Cp>Dear Ms. Mei:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your acidified food facility located at 10 Minzhi Rd. Tongluo Township, Miaoli County, Taiwan 366001 on May 24 through May 27, 2024. During that inspection we found that your firm had serious deviations from the Emergency Permit Control regulation (Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, that lists the serious deviations found at your firm. We received your written response dated June 11, 2024. Our evaluation found your response was not adequate, as further described in this letter.\u003C\u002Fp>\u003Cp>As a manufacturer of thermally processed acidified foods intended for export to the United States (U.S.), you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of acidified food products. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR 108.25, including registration, and filing of process information, and the mandatory requirements in 21 CFR Part 114.\u003C\u002Fp>\u003Cp>Regulations specific to the processing of acidified foods are described in 21 CFR Part 108 and 21 CFR Part 114. As outlined in these regulations, a commercial processor that does not adhere to all the mandatory requirements of 21 CFR 108.25 and 21 CFR Part 114 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. § 344). As stated in 21 CFR 108.25(j) for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. § 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.25 and 21 CFR 114 renders your acidified food products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and acidified food regulations through links in FDA’s home page at www.fda.gov.\u003C\u002Fp>\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\u003Cp>1. A commercial processor of acidified foods must register as a food canning establishment and file a form FDA 2541 (food canning establishment registration) with the FDA within 10 days after first engaging in the manufacture, processing, or packing, as required by 21 CFR 108.25(c)(1), However, you did not register as a food canning establishment (FCE) before shipping your acidified fruit-flavored popping boba pearls to the U.S.\u003C\u002Fp>\u003Cp>Your response did not address your lack of food canning establishment registration. As of September 10, 2024, you have not registered as a Food Canning Establishment although you continue to ship fruit-flavored boba pearls to the U.S. as recently as September 6, 2024. If you plan to continue shipping to the U.S., you must register as described above.\u003C\u002Fp>\u003Cp>2. As a commercial processor engaged in the processing of acidified foods, you must provide the FDA information as to the scheduled processes, for each acidified food in each container size before shipping to the U.S., as required by 21 CFR 108.25(c)(2). As of the date of this letter, none of your firm’s acidified food scheduled processes have been filed with FDA. Scheduled process information for acidified foods must be submitted on Form FDA 2541e Food Process Filing for Acidified Method. Specifically, you manufacture ready-to-eat, shelf stable acidified popping boba pearls in various fruit flavors including, but not limited to strawberry, peach, and mango flavored popping boba pearls shipped to the U.S.; however, you have not filed a scheduled process for any of the boba pearls.\u003C\u002Fp>\u003Cp>In addition, your manager told our investigator that you had not had a scheduled process for your shelf-stable boba pearls established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods, as required by 21 CFR 114.83. During the inspection, your manager explained that the ingredients are not weighed according to a recipe and there were no written recipes for the production staff to follow to ensure pH is consistent between batches. Your manager also stated he does not routinely test the pH. During the inspection, your manager measured the pH of boba pearls in the warehouse at random and found the pH to be \u003Cstrong>(b)(4)\u003C\u002Fstrong> for mango-flavored boba pearls shipped to the U.S. You must ensure that you are correctly measuring the finished equilibrium pH of the acidified boba pearls to ensure it is less than 4.6 and does not exceed the maximum equilibrium pH value as determined by a qualified person with expert knowledge as described above.\u003C\u002Fp>\u003Cp>Your response included a summary of your planned and completed corrective actions including, developing “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” enrolling personnel in HACCP certifications and acidic food courses within three months, and a 3rd party certification service conducting a product sterilization certification by the end of July 2024. You stated you would, upon completion of the certification, share the results of the certification with us. However, to date, you have not provided training records, third-party certifications, or evidence demonstrating you have had your scheduled processes for your shelf-stable boba pearls established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods (“process authority”), as required by 21 CFR 114.83. Nor have you filed your scheduled processes with us. In your response to this Warning Letter, you should provide the information regarding the qualified person who is collecting the scientific data to support your scheduled process if you intend to export acidified foods to the U.S. You should also provide information regarding your intent to file you scheduled processes established by a qualified individual as described above. You should also provide five (5) consecutive days of completed monitoring records demonstrating you are following your scheduled process established by a process authority to ensure you are meeting your established pH and thermal processing critical parameters.\u003C\u002Fp>\u003Cp>In your response you also provided third-party test reports for \u003Cem>Staphylococcus aureus, Salmonella, Listeria monocytogenes\u003C\u002Fem>, and \u003Cem>Aerobic Plate Count\u003C\u002Fem>. While it is important to control these microorganisms, the main pathogen of concern in acidified foods is \u003Cem>Clostridium botulinum (C. botulinum). C. botulinum\u003C\u002Fem> is a bacterium commonly found in soil. It can produce a nerve toxin (botulinum toxin) under anaerobic conditions such as those in canned foods. Botulinum toxin can cause botulism, a rare but serious paralytic illness that can be fatal and is considered a medical emergency. In the case of acidified foods, you must control the finished equilibrium pH &lt; 4.6 and ensure other spoilage organisms are not present such that they may grow in the product thereby resulting in a pH &gt; 4.6. Furthermore, finished product testing alone is not sufficient to demonstrate acidified foods are safe for human consumption, you must also demonstrate you are in compliance with the Acidified Food regulations in 21 CFR Parts 108 and 114.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\u003C\u002Fp>\u003Cp>If you do not respond to this letter or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. 381(a)) including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, examples of Import Alerts that convey information specific to foreign firms that are not in compliance with the acidified food regulations (21 CFR 108 and 114) are Import Alert #99-37, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes and Import Alert #99-38, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods due to Inadequate Process Control. These alerts can be found on FDA’s web site at: www.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that you operate in compliance with the Act and all applicable FDA regulations, including Acidified Foods regulation (21 CFR Part 114), and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). For example, if you do resume exportation of acidified foods to the U.S. you must ensure you have adequate controls in place to ensure finished equilibrium pH &lt; 4.6 and each container bears an identifying code to specify the establishment where the product was packed and the product contained within (21 CFR 114.80(a) and (b). You have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\u003C\u002Fp>\u003Cp>We also offer the following comment in response to you telling our investigator that you do not export directly to the U.S. and do not know your U.S. consignees. You stated you ship to local distributors who ship to the U.S. FDA is aware of situations where adulterated foods manufactured in another country may be shipped illegally to the U.S. This is sometimes referred to as the “gray market.” Section 801(m)(1) of the Act (21 U.S.C. 381(m)(1)) states that prior notice must be submitted for the article of food and it must contain the identity of the manufacturer of the food being imported or offered for import. Accordingly, the automated commercial environment (ACE) filer must submit at the time of filing entry for an acidified food, the Food Canning Establishment Number (FCE) and the Submission Identifier (scheduled process number) and can dimensions or volume, as required by 21 CFR 1.73(c). We recommend that you inform your customers that your firm does not have an FCE, and your acidified food products do not have scheduled processes that have been filed with FDA, so there is no FCE or scheduled process number that can be provided in the prior notice. A failure to properly file an acidified food offered for import to the U.S. may result in the detention and refusal of the acidified food.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration via email to Victoria.Wagoner@fda.hhs.gov. If sending a response by mail address to Food and Drug Administration Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 690671 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Food Safety\u003Cbr>&nbsp; &nbsp;and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTseng C. Mei\n\nRecipient Title\n\nChairman of the Board\n\nDalai Biotech Company Ltd\n\n10 Minzhi Rd.\n\nTongluo Township, Miaoli County 366001\n\nTaiwan\n\ndalai@lailai3211.com.tw\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nWARNING LETTER\nReference No. 690671\nDear Ms. Mei:\nThe United States Food and Drug Administration (FDA) inspected your acidified food facility located at 10 Minzhi Rd. Tongluo Township, Miaoli County, Taiwan 366001 on May 24 through May 27, 2024. During that inspection we found that your firm had serious deviations from the Emergency Permit Control regulation (Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108) and the Acidified Foods regulation (21 CFR Part 114). At the conclusion of the inspection, the FDA investigator issued an FDA-483, Inspectional Observations, that lists the serious deviations found at your firm. We received your written response dated June 11, 2024. Our evaluation found your response was not adequate, as further described in this letter.\nAs a manufacturer of thermally processed acidified foods intended for export to the United States (U.S.), you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of acidified food products. The Emergency Permit Control regulations were issued, in part, pursuant to section 404 of the Act, Emergency Permit Control, 21 U.S.C. § 344. A temporary emergency permit may be required for acidified foods whenever a processor has failed to fulfill the requirements of 21 CFR 108.25, including registration, and filing of process information, and the mandatory requirements in 21 CFR Part 114.\nRegulations specific to the processing of acidified foods are described in 21 CFR Part 108 and 21 CFR Part 114. As outlined in these regulations, a commercial processor that does not adhere to all the mandatory requirements of 21 CFR 108.25 and 21 CFR Part 114 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. § 344). As stated in 21 CFR 108.25(j) for imported products, in lieu of issuing an order of determination that a permit is required before products from a commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. § 381) when offered for entry into the United States. Violation of the mandatory requirements set forth in 21 CFR 108.25 and 21 CFR 114 renders your acidified food products adulterated within the meaning of section 402(a)(4) of the Act, 21 U.S.C. 342(a)(4). You can find the Act and acidified food regulations through links in FDA’s home page at www.fda.gov.\nYour significant violations are as follows:\n1. A commercial processor of acidified foods must register as a food canning establishment and file a form FDA 2541 (food canning establishment registration) with the FDA within 10 days after first engaging in the manufacture, processing, or packing, as required by 21 CFR 108.25(c)(1), However, you did not register as a food canning establishment (FCE) before shipping your acidified fruit-flavored popping boba pearls to the U.S.\nYour response did not address your lack of food canning establishment registration. As of September 10, 2024, you have not registered as a Food Canning Establishment although you continue to ship fruit-flavored boba pearls to the U.S. as recently as September 6, 2024. If you plan to continue shipping to the U.S., you must register as described above.\n2. As a commercial processor engaged in the processing of acidified foods, you must provide the FDA information as to the scheduled processes, for each acidified food in each container size before shipping to the U.S., as required by 21 CFR 108.25(c)(2). As of the date of this letter, none of your firm’s acidified food scheduled processes have been filed with FDA. Scheduled process information for acidified foods must be submitted on Form FDA 2541e Food Process Filing for Acidified Method. Specifically, you manufacture ready-to-eat, shelf stable acidified popping boba pearls in various fruit flavors including, but not limited to strawberry, peach, and mango flavored popping boba pearls shipped to the U.S.; however, you have not filed a scheduled process for any of the boba pearls.\nIn addition, your manager told our investigator that you had not had a scheduled process for your shelf-stable boba pearls established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods, as required by 21 CFR 114.83. During the inspection, your manager explained that the ingredients are not weighed according to a recipe and there were no written recipes for the production staff to follow to ensure pH is consistent between batches. Your manager also stated he does not routinely test the pH. During the inspection, your manager measured the pH of boba pearls in the warehouse at random and found the pH to be (b)(4) for mango-flavored boba pearls shipped to the U.S. You must ensure that you are correctly measuring the finished equilibrium pH of the acidified boba pearls to ensure it is less than 4.6 and does not exceed the maximum equilibrium pH value as determined by a qualified person with expert knowledge as described above.\nYour response included a summary of your planned and completed corrective actions including, developing “(b)(4),” enrolling personnel in HACCP certifications and acidic food courses within three months, and a 3rd party certification service conducting a product sterilization certification by the end of July 2024. You stated you would, upon completion of the certification, share the results of the certification with us. However, to date, you have not provided training records, third-party certifications, or evidence demonstrating you have had your scheduled processes for your shelf-stable boba pearls established by a qualified person who has expert knowledge acquired through appropriate training and experience in the acidification and processing of acidified foods (“process authority”), as required by 21 CFR 114.83. Nor have you filed your scheduled processes with us. In your response to this Warning Letter, you should provide the information regarding the qualified person who is collecting the scientific data to support your scheduled process if you intend to export acidified foods to the U.S. You should also provide information regarding your intent to file you scheduled processes established by a qualified individual as described above. You should also provide five (5) consecutive days of completed monitoring records demonstrating you are following your scheduled process established by a process authority to ensure you are meeting your established pH and thermal processing critical parameters.\nIn your response you also provided third-party test reports for Staphylococcus aureus, Salmonella, Listeria monocytogenes, and Aerobic Plate Count. While it is important to control these microorganisms, the main pathogen of concern in acidified foods is Clostridium botulinum (C. botulinum). C. botulinum is a bacterium commonly found in soil. It can produce a nerve toxin (botulinum toxin) under anaerobic conditions such as those in canned foods. Botulinum toxin can cause botulism, a rare but serious paralytic illness that can be fatal and is considered a medical emergency. In the case of acidified foods, you must control the finished equilibrium pH \u003C 4.6 and ensure other spoilage organisms are not present such that they may grow in the product thereby resulting in a pH > 4.6. Furthermore, finished product testing alone is not sufficient to demonstrate acidified foods are safe for human consumption, you must also demonstrate you are in compliance with the Acidified Food regulations in 21 CFR Parts 108 and 114.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. Responding in English will help to assist us in our review of your documentation.\nIf you do not respond to this letter or if we find your response inadequate, we may take further action. For instance, we may take action to refuse admission of your imported acidified food products under section 801(a) of the Act (21 U.S.C. 381(a)) including placing them on detention without physical examination (DWPE). FDA’s DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA’s Import Alerts. For your information, examples of Import Alerts that convey information specific to foreign firms that are not in compliance with the acidified food regulations (21 CFR 108 and 114) are Import Alert #99-37, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods without Filed Scheduled Processes and Import Alert #99-38, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods due to Inadequate Process Control. These alerts can be found on FDA’s web site at: www.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that you operate in compliance with the Act and all applicable FDA regulations, including Acidified Foods regulation (21 CFR Part 114), and the Current Good Manufacturing Practice regulation (21 CFR Part 117, Subpart B). For example, if you do resume exportation of acidified foods to the U.S. you must ensure you have adequate controls in place to ensure finished equilibrium pH \u003C 4.6 and each container bears an identifying code to specify the establishment where the product was packed and the product contained within (21 CFR 114.80(a) and (b). You have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations. You also have a responsibility to use procedures to prevent further violations of the Act and all applicable regulations.\nWe also offer the following comment in response to you telling our investigator that you do not export directly to the U.S. and do not know your U.S. consignees. You stated you ship to local distributors who ship to the U.S. FDA is aware of situations where adulterated foods manufactured in another country may be shipped illegally to the U.S. This is sometimes referred to as the “gray market.” Section 801(m)(1) of the Act (21 U.S.C. 381(m)(1)) states that prior notice must be submitted for the article of food and it must contain the identity of the manufacturer of the food being imported or offered for import. Accordingly, the automated commercial environment (ACE) filer must submit at the time of filing entry for an acidified food, the Food Canning Establishment Number (FCE) and the Submission Identifier (scheduled process number) and can dimensions or volume, as required by 21 CFR 1.73(c). We recommend that you inform your customers that your firm does not have an FCE, and your acidified food products do not have scheduled processes that have been filed with FDA, so there is no FCE or scheduled process number that can be provided in the prior notice. A failure to properly file an acidified food offered for import to the U.S. may result in the detention and refusal of the acidified food.\nPlease send your reply to the Food and Drug Administration via email to Victoria.Wagoner@fda.hhs.gov. If sending a response by mail address to Food and Drug Administration Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding this letter, you may contact Victoria Wagoner via email at Victoria.Wagoner@fda.hhs.gov. Please reference 690671 on any submissions and within the subject line of any emails to us.\nSincerely,\n\u002FS\u002F\nAnn M. Oxenham, J.D.\nDirector\nOffice of Compliance\nCenter for Food Safety\nand Applied Nutrition","Dalai Biotech Company Ltd","dalai-biotech-company-ltd-690671-09302024","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdalai-biotech-company-ltd-690671-09302024","2026-10-26T08:08:21.118649+00:00","2025-05-20","690671","Food & Beverages","Tseng C. Mei","2026-08-19T16:45:33.119+00:00","Via Express Delivery","2024-09-30",3,{"510k":76,"classification":77,"enforcement":78,"event":79,"event_backfill":80,"pma":81,"warning_letter":82},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]